BioFire
BioFire Dx Receives First FDA Marketing Clearance for SARS-CoV-2 Respiratory Panel
The test is the first COVID-19 assay to transition from Emergency Use Authorization to a cleared regulatory status.
Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.
BioMérieux Coronavirus Test Gets FDA OK for Use With Pooled Samples
The test, developed by BioMérieux subsidiary BioFire Defense, first received Emergency Use Authorization from the US Food and Drug Administration in March.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
BioMérieux Q3 Revenues Increase 21 Percent
The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.
Feb 26, 2020
BioMérieux Reports 11 Percent Revenue Growth in Q4
Jan 14, 2020
BioMérieux Submits 43-Target BCID2 Test to FDA
Apr 30, 2019
Apr 24, 2019
BioMérieux Q1 Revenues Up 8 Percent
Feb 27, 2019
BioMérieux Reports 10 Percent Revenue Growth in Q4
Dec 26, 2018